Show simple item record

dc.contributor.authorÇekdemir, Demet
dc.contributor.authorGüvenç, Serkan
dc.contributor.authorÖzdemirkıran, Füsun
dc.contributor.authorEser, Ali
dc.contributor.authorToptaş, Tayfur
dc.contributor.authorÖzkocaman, Vildan
dc.contributor.authorHaydaroğlu Şahin, Handan
dc.contributor.authorErmiş Turak, Esra
dc.contributor.authorEsen, Ramazan
dc.contributor.authorCömert, Melda
dc.contributor.authorSadri, Sevil
dc.contributor.authorAslaner, Müzeyyen
dc.contributor.authorUncu Ulu, Bahar
dc.contributor.authorKarakuş, Abdullah
dc.contributor.authorBapur, Derya Selim
dc.contributor.authorAlacacıoğlu, İnci
dc.contributor.authorAydın, Demet
dc.contributor.authorTekinalp, Atakan
dc.contributor.authorNamdaroğlu, Sinem
dc.contributor.authorCeran, Funda
dc.contributor.authorTarkun, Pınar
dc.contributor.authorKiper, Demet
dc.contributor.authorÇetiner, Mustafa
dc.contributor.authorYenerel, Mustafa
dc.contributor.authorDemir, Ahmet Muzaffer
dc.contributor.authorYılmaz, Güven
dc.contributor.authorTerzi, Hatice
dc.contributor.authorAtilla, Erden
dc.contributor.authorMalkan, Ümit Yavuz
dc.contributor.authorAcar, Kadir
dc.contributor.authorÖztürk, Erman
dc.contributor.authorTombak, Anıl
dc.contributor.authorSunu, Cenk
dc.contributor.authorSalim, Ozan
dc.contributor.authorAlayvaz, Nevin
dc.contributor.authorSayan, Özkan
dc.contributor.authorOzan, Ülkü
dc.contributor.authorAyer, Mesut
dc.contributor.authorGökgöz, Zafer
dc.contributor.authorAndıç, Neslihan
dc.contributor.authorKızılkılıç, Ebru
dc.contributor.authorNoyan, Figen
dc.contributor.authorÖzen, Mehmet
dc.contributor.authorPepedil Tanrıkulu, Funda
dc.contributor.authorAlanoğlu, Güçhan
dc.contributor.authorÖzkan, Hasan Atilla
dc.contributor.authorAslan, Vahap
dc.contributor.authorÇetin, Güven
dc.contributor.authorAkyol Erikçi, Alev
dc.contributor.authorDeveci, Burak
dc.contributor.authorErsoy Dursun, Fadime
dc.contributor.authorDermenci, Hasan
dc.contributor.authorAytan, Pelin
dc.contributor.authorGündüz, Mehmet
dc.contributor.authorKarakuş, Volkan
dc.contributor.authorÖzlü, Can
dc.contributor.authorDemircioğlu, Sinan
dc.contributor.authorAkay Yanar, Olga Meltem
dc.contributor.authorÖzatlı, Düzgün
dc.contributor.authorÜndar, Levent
dc.contributor.authorTiftik, Eyüp Naci
dc.contributor.authorTürköz Sucak, Ayhan Gülsan
dc.contributor.authorHaznedaroğlu, İbrahim
dc.contributor.authorÖzcan, Muhit
dc.contributor.authorŞencan, Mehmet
dc.contributor.authorTombuloğlu, Murat
dc.contributor.authorÖzet, Gülsüm
dc.contributor.authorBilgir, Oktay
dc.contributor.authorTurgut, Burhan
dc.contributor.authorÖzcan, Mehmet Ali
dc.contributor.authorPayzın, Kadriye Bahriye
dc.contributor.authorSönmez, Mehmet
dc.contributor.authorAyyıldız, Orhan
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorErtop, Şehmus
dc.contributor.authorTurgut, Mehmet
dc.contributor.authorSoysal, Teoman
dc.contributor.authorKaya, Emin
dc.contributor.authorÜnal, Ali
dc.contributor.authorPehlivan, Mustafa
dc.contributor.authorAtagündüz, Işık
dc.contributor.authorTuğlular Fıratlı, Tülin
dc.contributor.authorSaydam, Güray
dc.contributor.authorDiz Küçükkaya, Reyhan
dc.date.accessioned2021-06-03T05:20:03Z
dc.date.available2021-06-03T05:20:03Z
dc.date.issued2019
dc.identifier.issn1300-7777
dc.identifier.urihttp://dx.doi.org/10.4274/tjh.galenos.2018.0307
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863031/
dc.identifier.urihttp://hdl.handle.net/11655/23972
dc.description.abstractObjective: The aim of the present study was to evaluate the efficacy and safety of eltrombopag, an oral thrombopoietin receptor agonist, in patients with chronic immune thrombocytopenia (ITP). Materials and Methods: A total of 285 chronic ITP patients (187 women, 65.6%; 98 men, 34.4%) followed in 55 centers were enrolled in this retrospective cohort. Response to treatment was assessed according to platelet count (/mm3) and defined as complete (platelet count of >100,000/mm3), partial (30,000-100,000/mm3 or doubling of platelet count after treatment), or unresponsive (<30,000/mm3). Clinical findings, descriptive features, response to treatment, and side effects were recorded. Correlations between descriptive, clinical, and hematological parameters were analyzed. Results: The median age at diagnosis was 43.9±20.6 (range: 3-95) years and the duration of follow-up was 18.0±6.4 (range: 6-28.2) months. Overall response rate was 86.7% (n=247). Complete and partial responses were observed in 182 (63.8%) and 65 (22.8%) patients, respectively. Thirty-eight patients (13.4%) did not respond to eltrombopag treatment. For patients above 60 years old (n=68), overall response rate was 89.7% (n=61), and for those above 80 years old (n=12), overall response rate was 83% (n=10). Considering thrombocyte count before treatment, eltrombopag significantly increased platelet count at the 1st, 2nd, 3rd, 4th, and 8th weeks of treatment. As the time required for partial or complete response increased, response to treatment was significantly reduced. The time to reach the maximum platelet levels after treatment was quite variable (1-202 weeks). Notably, the higher the maximum platelet count after eltrombopag treatment, the more likely that side effects would occur. The most common side effects were headache (21.6%), weakness (13.7%), hepatotoxicity (11.8%), and thrombosis (5.9%). Conclusion: Results of the current study imply that eltrombopag is an effective therapeutic option even in elderly patients with chronic ITP. However, patients must be closely monitored for response and side effects during treatment. Since both response and side effects may be variable throughout the follow-up period, patients should be evaluated dynamically, especially in terms of thrombotic risk factors.
dc.language.isoen
dc.relation.isversionof10.4274/tjh.galenos.2018.0307
dc.rightsAttribution 4.0 United States
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleA Multi-Center Study On The Efficacy Of Eltrombopag In Management Of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience
dc.title.alternativeA Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalTurkish Journal Of Hematology
dc.contributor.departmentİç Hastalıkları
dc.identifier.volume36
dc.identifier.issue4
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus


Files in this item

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 United States
Except where otherwise noted, this item's license is described as Attribution 4.0 United States